1. Introduction {#s0005}
===============

Current requirements in the hemostasis laboratory include optimal diagnostic performance, improved quality management, and efficient work-flow. The high-volume blood coagulation analyzer Sysmex CS-5100 System™ (Siemens Healthcare Diagnostics, Erlangen, Germany) is fully automated and has been developed for routine coagulation diagnostics in large hospitals.

The investigation of hemostasis has always been an important aspect of laboratory diagnostics. With the growing number of samples which a laboratory must handle, a fast, precise and robust analyzer is essential. Furthermore, any new analyzer should require minimal operational and maintenance time, and have a small sample and dead volume in order to analyze pediatric samples.

In modern laboratories most analyzers used for clinical chemistry, hematology and hemostaseology are automated for shorter turn-around-time (TAT) (especially for samples from the emergency room and intensive care unit) and to minimize the personnel needed to operate them Any new coagulation analyzer must be compatible with such systems for measuring the standard parameters (PT, PTT, fibrinogen, antithrombin, d-dimer). In particular, in laboratories associated with blood transfusion services, the precise measurement of single-factor activity is necessary to obtain all the official licenses required. The system should also perform more specific assays e.g. Protein C, Protein S, von Willebrand assays.

The operation of the analyzer and the software must be simple and intuitive because the technical staff must be able to work with the various analyzers (e.g. clinical chemistry and hemostaseology) concurrently.

2. Materials and methods {#s0010}
========================

2.1. Sample collection and preparation {#s0015}
--------------------------------------

Leftover citrated plasma from patient samples was used to evaluate the system. Blood was collected in 2.9 mL tubes containing 290 µL sodium citrate (100 mmol/L) (KABE Labortechnik GmbH, Nümbrecht, Germany). Blood was centrifuged for 10 min at 3000×*g* for prothrombin time (PT), partial thromboplastin time (PTT), antithrombin (AT), fibrinogen (Fib) and D-dimer. For specific hemostaseological tests (factor II (FII), factor V (FV), factor VII (FVII), factor VIII (FVIII), factor IX (FIX), factor X (FX), factor XI (FXI), factor (FXII), factor XIII (FXIII), protein C (PC), von Willebrand factor antigen (VWF Ag), von Willebrand factor activity (VWF Ac), activated protein C-resistance (APC-resistance)) plasma was again centrifuged at 3000×*g* for 10 min (room temperature), frozen at −20 °C for a maximum of one week and analyzed in batches.

2.2. The analyzer {#s0020}
-----------------

The Sysmex CS-5100 System is a fully automated, computer-interfaced coagulation analyzer intended for in vitro diagnostic use. The analyzer has 36 incubation wells and 20 measurement channels. The Sysmex system is able to perform clotting, chromogenic and immunological tests. The absorbance measurement unit uses a halogen lamp with 340, 405, 575, 660, and 800 nm wavelengths.

The analyzer can hold 10 racks with 10 samples per rack, with capability to mix primary tubes from different manufacturers on the same rack at the same time. It has an additional cap-piercing sample arm, which processes capped and uncapped sample tubes. Up to 40 reagents can be stored on board using the rack system, which are all cooled at 10 °C ±2 °C. Five extra positions at ambient temperature are dedicated for buffer or rinse solution. Additionally, there are five STAT positions which can be loaded continuously; the analyzer will immediately start measuring the samples. Samples, controls and reagents are identified by barcode readers. As Control plasma can be included in the reagent area, so measurement of controls can be performed at any time, for instance when a new vial of reagent is used. It is also possible to run the control from a 4 mL cup loaded on a sample rack to avoid reducing the number of reagent positions available.

During measurement, it is possible to load cuvettes (up to 1000) and samples continuously. If reagents need to be changed, the system will stop the run at the next feasible time.

Sophisticated software algorithms record, monitor, and check reaction kinetics to determine the correct clotting time. In addition, the system provides an overview of all loaded reagents showing the number of remaining tests and the time since the reagent was uploaded into the analyzer. Connection to the system manager is optional.

The analyzer performs an automatic hemolysis, icterus and lipemia check with a preanalytical scan of patient samples performed at two wavelengths (575 nm and 660 nm). A primary tube sample volume check identifies insufficient sample volume.

2.3. Reagents {#s0025}
-------------

The reagents and calibrators used on the CS-5100 and CS-2000*i* for this study are listed in [Table 1](#t0005){ref-type="table"}. All assays were performed according to the manufacturers' specifications and standard laboratory methods.Table 1Reagents and calibrators used on the CS-5100/CS-2000*i* analyzers for the comparison study.Table 1**Siemens Healthcare Diagnostics Products GmbHTestReagent/Calibrator/Control**PTThromborel® S/ PT Multi Calibrator/Control Plasma N, Control Plasma P, Dade® Ci-Trol® 2Dade Innovin®/ PT Multi Calibrator/Control Plasma N, Control Plasma P, Dade Ci-Trol 2 APTTDade Actin® FSL/ - /Control Plasma N, Dade Ci-Trol 2Pathromtin® SL/ - /Control Plasma N, Dade Ci-Trol 2 FibDade Thrombin-Reagent/Standard Human Plasma/ Control Plasma N, Control Plasma P FII/ FV/ FVII/ FXDade Innovin/ Standard Human Plasma/Control Plasma N, Control Plasma P FVIII/ FIX/ FXI/ FXIIDade Actin FSL/Standard Human Plasma/Control Plasma N, Control Plasma P F XIIIBerichrom® FXIII/Standard Human Plasma/Control Plasma N, Control Plasma P ATINNOVANCE® Antithrombin/Standard Human Plasma/Control Plasma N, Control Plasma P D-DimerINNOVANCE D-Dimer/INNOVANCE D-Dimer Cal/INNOVANCE D-Dimer Control 1 + 2 VWF AcINNOVANCE VWF Ac/Standard Human Plasma/ Control Plasma N, Control Plasma P VWF Agvon Willebrand Antigen/ Standard Human Plasma/ Control Plasma N, Control Plasma P TTTest Thrombin Reagent/ - /Control Plasma N, Control Plasma P PCProtein C Reagent/Standard Human Plasma/ Control Plasma N, Control Plasma P APCProC® Ac R/ - /Control Plasma N, ProC Control Plasma**Instrumental Laboratory** **TestReagent/Calibrator/Control** PTHemosIL Recombi PlasTin 2 G/HemosIL Calibration Plasma/HemosIL Normal Control, HemosIL Low Abnormal Control APTTHemosIL SynthASil/ - /HemosIL Normal Control, HemosIL Low Abnormal ControlAPTT-SP (liquid)/ - /HemosIL Normal Control, HemosIL Low Abnormal Control FibHemosIL Q.F.A. Thrombin (Bovine)/HemosIL Calibration Plasma/HemosIL Normal Control, HemosIL Low Abnormal Control FII/ FV/ FVII/ FXHemosIL Factor II/ V/ VII/ X deficient plasma/HemosIL Calibration Plasma/HemosIL Normal Control, HemosIL Special Test Control Level 2 FVIII/ FIX/ FXI/ FXIIHemosIL Factor VIII/ IX/ XI/ XII deficient plasma/HemosIL Calibration Plasma/HemosIL Normal Control, HemosIL Special Test Control Level 2 F XIIIHemosIL Factor XIII Antigen/ HemosIL Calibration Plasma/HemosIL Normal Control, HemosIL Special Test Control Level 2 ATHemosIL Antithrombin/ HemosIL Calibration Plasma/HemosIL Normal Control, HemosIL Low Abnormal Control D-DimerHemosIL D-Dimer HS 500/ HemosIL D-Dimer HS 500 Calibrator/HemosIL D-Dimer HS 500 Controls VWF AcHemosIL VWF Ac/HemosIL Calibration Plasma/HemosIL Normal Control, HemosIL Special Test Control Level 2 VWF AgHemosIL VWF Ag/HemosIL Calibration Plasma/HemosIL Normal Control, HemosIL Special Test Control Level 2 TTHemosIL Thrombinzeit/ - /HemosIL Normal Control, HemosIL Low Abnormal Control PCHemosIL ProC/ HemosIL Calibration Plasma/ HemosIL Normal Control, HemosIL Special Test Control Level 2 APCHemosIL Factor V Leiden/ - /HemosIL APC Control Plasma Level 1 + 2[^2]

2.4. Methods {#s0030}
------------

The study was designed in order to evaluate the Sysmex CS-5100 in terms of hardware/software quality and in routine use. Therefore, patient samples were measured with both the CS-5100 and CS-2000*i* as well as the ACL TOP. Several aspects of the study, e.g. test samples and storage were performed based on the CLSI EP9-A2 guidelines (CLSI, Wayne, PA, USA), which we followed. After independently training two technicians, a robustness test of both Sysmex analyzers was performed over five weeks. During this period, an average of 128 samples a day (range 36--186) and a total of 3093 samples was analyzed. The same procedure was performed by the second technician for two more weeks, analyzing an average of 130 (range 67--243) samples per day and 1684 samples in total.

Imprecision was determined using the following commercial quality control materials at different concentration levels: Control Plasma N (CPN), Control Plasma P (CPP), Dade Ci-Trol 2 (Citrol 2), INNOVANCE D-Dimer Control 1, INNOVANCE D-Dimer Control 2 ([Table 1](#t0005){ref-type="table"}). All control preparations were obtained from Siemens Healthcare Diagnostics Products GmbH (Marburg, Germany). The coefficient of variation (CV) for each material was calculated based on the daily results of measured samples.

A stress test was performed over three days. On day one the CS-5100 was used for nonstop measurement over five hours with the analysis of routine tests and a small number of specific hemostaseological ones. STAT samples were inserted randomly in the CS-5100 during the stress test. During the test, under filled bottles were used to induce a change of reagent vials. As primary tubes, pediatric tubes, and sample cups can be loaded onto the same rack, this was additionally tested under stress conditions. One the second day the analyzer was continuously loaded with samples over five hours with routine preparation of the analyzer. The throughput of the CS-5100 and ACL TOP was evaluated using the same 100 routine samples with request for PT (*n*=100), PTT (*n*=80), AT (*n*=20) and d-dimer (*n*=10). STAT capability was determined by the processing time of two STAT samples for the same four assays. Finally, on day three the barcode reader was tested using unclear barcodes, e.g. wet or damaged barcodes, on various tubes. A 24-h test was also conducted in order to simulate a routine day including reagent changes, maintenance and a shutdown of the system during which time samples were continuously delivered for measurement.

2.5. Statistical evaluation {#s0035}
---------------------------

The method comparison study data were evaluated by Siemens Healthcare Diagnostics Products GmbH using the statistical software SAS V9.1. Passing-Bablok regression analysis as well as Bland-Altman analysis were performed. For Passing Bablok regression we deemed an acceptable comparison to be a slope of 1.0±0,1 and a correlation coefficient *r*\>0,95.

3. Results {#s0040}
==========

3.1. Inter-assay precision {#s0045}
--------------------------

As shown in [Table 2](#t0010){ref-type="table"}A, the inter-assay CVs (PT, PTT, Fib, AT) were below 3.51% for the parameters measured in controls (normal and pathological range) using the CS-5100, consistent with previous studies [@bib1], [@bib2]. The same was true for the CS-2000*i*, with inter-assay CVs below 5.1%. The CV for specific coagulation parameters such as FVIII, FXIII, VWF Ag, VWF Ac was also calculated when a minimum of 6 analyses of controls had been performed ([Table 2](#t0015){ref-type="table"}B). Exceptionally, D-dimer measurement showed a higher CV for the pathological control (11.41%) whereas the normal control had a lower CV of 4.26%.Table 2AInter-assay precision of the CS-5100 and CS-2000*i* analyzers for routine tests.Table 2A**CS5100CS2000*i*TestControlUnit*****n*****Mean±SDCV (%)*****n*****Mean±SDCV (%)**PT (Dade INNOVIN)N%2885.5±2.172.542586±2.572.99PT (Dade INNOVIN)P%2536.4±0.541.472836.3±0.691.89INRN281.07±0.010.92251.07±0.021.45INRP251.81±0.031.4281.81±0.031.65PT (Thromborel S)N%3280.8±2.833.513387.2±4.144.75PT (Thromborel S)P%3340.5±1.182.913241.3±2.115.1INRN321.11±0.021.99331.07±0.032.65INRP331.80±0.052.61321.77±0.084.52APTT (Dade Actin FSL)Ns3327.1±0.170.633327±0.260.95APTT (Dade Actin FSL)C2s3348.7±0.661.353348.7±0.671.38APTT (Pathromtin SL)Ns3231.5±0.852.73231.9±0.391.23APTT (Pathromtin SL)C2s3262.4±0.651.043262.7±1.011.61FibrinogenNg/L542.43±0.062.29532.36±0.093.64FibrinogenPg/L530.81±0.022.15540.79±0.033.34AntithrombinN%5094.5±2.152.284895.4±3.143.29AntithrombinP%4831.9±1.013.155033.3±1.444.33INNOVANCE D-DimerD1mg/L210.35±0.014.26210.32±0.0310.74INNOVANCE D-DimerD2mg/L232.58±0.2911.41222.55±0.210.43[^3]Table 2BInter-assay precision of the CS-5100 and CS-2000*i* analyzers for special coagulation parameters.Table 2B**TestControlUnit*****n*****CS5100*****n*****CS2000iMean±SDCV (%)Mean±SDCV (%)**F IIN%889.5±2.552.86893.5±2.853.04P%831.3±0.92.88831±0.842.72F VN%892.2±2.532.75888.8±5.796.52P%829.1±3.983.98829.6±2.157.27F VIIN%683.5±2.923.5686.6±4.675.39P%634.8±0.752.15635.6±1.032.89F VIIIN%1987.2±3.133.591989.6±6.226.94P%1827.3±1.134.132127.3±2.489.08F IXN%890.9±2.42.641583.8±7.28.59P%831.7±2.182.18928.6±2.689.37F XN%684.4±2.863.38692.3±5.255.69P%631.5±0.973.08631.5±1.23.81F XIN%692.6±3.463.746101.2±3.853.81P%629.1±0.240.84628.7±1.254.37F XIIN%690±4.054.51693±5.826.26P%832.7±3.8411.75630.1±3.110.33F XIIIN%1085.1±2.262.651581.2±7.539.28P%1226.0±1.5661320.7±2.7610.89VWF Ag medN%16109.9±2.20216114.7±2.271.98P%1640.1±1.132.821640.9±1.202.93INNOVANCE VWF Ac medN%1492.6±1.952.111497.7±6.436.59P%1428.9±0.471.621428.2±1.374.88Protein CN%895.2±7.197.55896±7.67.92P%832.4±1.976.08835.4±3.5510.02APC resistance (ratio)N%83.16±0.134.17103.12±0.154.93P%81.15±0.021.6481.17±0.021.33[^4]

3.2. Method comparison study {#s0050}
----------------------------

The results of the correlation study between the CS-5100, CS-2000*i* and ACL TOP are shown for PT, PTT, Fib and AT [Fig. 1](#f0005){ref-type="fig"}(A--D) and for PT, PTT, Fib and AT in [Table 3A](#t0020){ref-type="table"}, [Table 3B](#t0025){ref-type="table"}. In addition, measurements of various coagulation factors were performed according to the individual requests. However, in view of the low numbers (*n*\<40), no further statistical analysis was conducted..Fig. 1Correlation of CS-5100 to CS-2000*i* for prothrombin time (PT) (A), partial thromboplastin time (PTT) (B), fibrinogen (C) and antithrombin (D).Fig. 1Table 3ACorrelation between the CS-5100 and the CS-2000*i* for the measurement of patients\' samples.Table 3A**CS-5100CS-2000*i*TestUnit*****n*****Absolute difference \|*y*--*x*\| (Mean)SlopeIntercept*****r****r***^**2**^**RangeMeanMedianRangeMeanMedian**PT (Dade Innovin)%22201.410.995+0.0350.9970.9957.7−137.459.854.55.6−42.260.155.1PT (Dade Innovin)s21470.361.021−0.1040.9990.9979.9−105.219.015.39.8−101.818.715.1INR22200.0211.000+0.0000.9990.9980.86− 6.291.651.340.86−6.731.651.33PT (Thromborel S)%13132.560.921+2.3490.9980.99611.3−132.355.854.411.6−136.25856.4PT (Thromborel S)s13130.410.992−0.0960.9980.99610.3 −66.919.616.410.6−65.320.016.7INR13130.0420.98+0.0530.9980.9960.87−6.321.731.420.85−6.291.721.4APTT (Dade Actin FSL)s16370.611.000−0.2000.9960.99321.7−101.136.634.321.9−101.436.834.5APTT (Pathromtin SL)s10040.960.986+0.2010.9970.99421.3−151.748.244.621.4−171.948.845.2Fibrinogeng/l6390.1070.972+0.0800.9930.9870.79−8.423.423.240.75−8.143.433.24Antithrombin%2552.980.952+3.1510.9580.91845.6−136.094.396.25.8−135.295.397.1[^5]Table 3BCorrelation between the CS-5100 and the ACL TOP for the measurement of patients' samples.Table 3BCS-5100ACL TOP**Reagent CS-5100Reagent ACL TOPUnit*****n*****Absolute difference \|*y*-*x*\| (Mean)SlopeInterceptr*****r***^**2**^**RangeMeanMedianRangeMeanMedian**PT (Dade Innovin)HemosIL Recombi PlasTin 2G%22105.020.971−1.1570.9810.9627.7−137.459,654,210−1526360PT (Dade Innovin)HemosIL Recombi PlasTin 2Gs21481.800.815+2.3040.9830.9669.9−105.219.015.38.6−98.920.316.3INR22210.1220.870+0.1330.9840.9680.86−6.291,651,340.77−6.431.731.41PT (Thromborel S)HemosIL Recombi PlasTin 2G%131312.180.772+3.7760.9780.95711.3−132.355.854.48−1816868PT (Thromborel S)HemosIL Recombi PlasTin 2Gs13132.280.889+2.9780.9600.92210.3−66.919.616.48.1−99.619.114.8INR13130.1731.000+0.1100.9640.9290.87−6.321.731.420.72−8.141.641.30APTT (Dade Actin FSL)HemosIL SynthASils16374.830.920−0.0120.8710.75921.7−101.136,634,320.7−160.739.836.8APTT (Pathromtin SL)HemosIL SynthASils10058.901.565−14.0240.8990.80821.3−151.748.244.518.3−126.539.836.3FibrinogenHemosIL Q.F.A. Thrombin (Bovine)g/l6410.3971.064+0.1890.9750.950.79−8.473.433.240.72−8.163.062.79AntithrombinHemosIL Antithrombin%2565.380.886+12.2790.9410.88645.6−136.094.496.324−1449393[^6]

The agreement between results obtained from different analyzers is demonstrated for PT, PTT, Fib and AT in difference-plots according to Bland and Altman ([Fig. 2](#f0010){ref-type="fig"}A--D). A complete list of all results is shown in [Table 4](#t0030){ref-type="table"}..Fig. 2Bland-Altman plots for prothrombin time (PT) (A), partial thromboplastin time (PTT) (B), fibrinogen (C) and antithrombin (AT) (D).Fig. 2Table 4Comparison of analyzers using Bland-Altman difference plots--summary of differences.Table 4**Test/unitReagentCS-5100/CS-2000*****i*****CS-5100/ACL TOP*****n*****Mean of differences (*x*--y) ±2SD*****n*****Mean of differences (*x*--y) ±2SD**PT \[s\]Dade Innovin21470.325 (−0.691, 1.341)2148−1.332 (−5.933, 3.268)Thromborel1313−0.324 (−1.392, 0.744)13130.573(−6.765, 7.911)PT \[%\]Dade Innovin2220−0.266 (−4.852, 4.320)2210−3.209 (−15.892, 9.474)Thromborel1313−2.155 (−7.716, 3.405)1313−11.666 (−29.791, 6.459)INRDade Innovin22200.006 (−0.072, 0.083)2221−0.081 (−0.400, 0.239)Thromborel13130.013 (−0.104, 0.129)13130.088 (−0.405, 0.580)PTT \[s\]Actin FSL1637−0.167 (−2.042, 1.708)1637−3.206 (−16.456, 10.043)Pathromtin SL1004−0.643 (−4.031, 2,744)10058.327 (−9.384, 26.038)FibrinogenDade Thrombin Reagent639−0.007 (−0.306, 0.293)6410.374 (−0.188, 0.936)AntithrombinINNOVANCE Antithrombin255−1.076 (−12.411, 10.260)2561.831 (−11.906, 15.567)

The small differences between the two analyzers are demonstrated using Bland-Altman plots which show that consideration of the differences is not essential for making clinical decisions. The Bland-Altman plot of PTT using Actin FSL reagent, for example, showed a mean time difference of −0.167 s with a ±2SD range of −2.042 to 1.708 s. This is clearly a strong indication of the good correlation between the two analyzers where no clinically relevant differences could be observed. Furthermore, the plots reveal no systematic bias and, as shown in [Fig. 2](#f0010){ref-type="fig"}A--D, there are also no deviations between the means of the two systems. However, although the results obtained from comparison of the two CS systems showed excellent correlation, small differences could be detected when we compared the ACL TOP to the CS-5100.

3.3. Interference {#s0055}
-----------------

Analytical interference with spectrophotometric methods occurs with hemolysis, bilirubin and lipids with laboratory assays. As a consequence, the altered results may lead to inappropriate further tests, incorrect interpretation, incorrect diagnosis and potentially needless intervention and unfavorable outcome for patients [@bib3]. The hemolysis, icterus and lipemia (HIL) check detects these potential interferences with using a photometric absorbance check on patient samples at relevant wavelengths.

To verify the ability of the CS-5100 to detect hemolytic and lipemic samples, two panels consisting of 37 and 4 samples, respectively, were identified by visual assessment and were quantified for free hemoglobin and triglycerides. As most of the hemostatic assays were not affected significantly by bilirubin, no further analyses of icteric samples were carried out in the study.

From the hemolytic sample panel 33 samples were confirmed by measurement of free hemoglobin \>50 mg/dL. This concentration has been shown to influence various spectrophotometric assays. The CS-5100 flagged 32 samples of these samples correctly (97%). Three samples were flagged but had free hemoglobin concentrations below 50 mg/dL (31 mg/dL, 39 mg/dL and 43 mg/dL) and one sample with a free hemoglobin concentration of 60 mg/dL was not flagged by the CS-5100.

Interference of lipids on hemostatic assays is supposed to be significant at \>150 mg/dL triglyceride [@bib4]. All four selected lipemic samples, were confirmed by measurement of triglycerides as \>400 mg/dL. The CS-5100 flagged all samples but one. The concentration of triglyceride in this sample was extremely high (943 mg/dL). This discrepancy may be caused by the fact that lipids vary greatly in size and composition, and thus true triglyceride concentrations do not always correlate with the results from photometric interference detection.

3.4. Stress test {#s0060}
----------------

On the first day of the stress test the analyzer had no problems with vial changes following used-up reagents or sample aspiration with different primary tubes and sample cups. STAT samples were given high priority when they were started. No major errors were observed during the first day instead of flags because of used-up reagent or quality control results outside the target intervals.

On the second day of the stress test, throughput of the CS-5100 was compared to the ACL TOP and determined by the processing times for testing 100 samples with a mixed assay profile (PT, PTT, AT and D-dimer; 210 results). The results of the throughput study are presented in [Table 5](#t0035){ref-type="table"}. The first result was shown by the ACL TOP analyzer after 6 min 10 s, whereas the CS-5100 finished the first sample after 8 min 28 s. For the measurement of all 100 samples, the CS-5100 was 38% faster (48 min 51 s) than the ACL TOP (67 min 24 s). STAT capability was determined by the processing time of two STAT samples for the same four assays. Although the CS-5100 required two minutes more to report the first result, it completed the full job list (218 results) 18 min ahead of the ACL TOP (27% faster). STAT processing was more than twice as fast with the CS-5100 compared to ACL TOP (55% faster).Table 5Throughput study of the CS-5100 analyzer compared to the current laboratory analyzer ACL TOP.Table 5**DeviceAssays (% of samples analyzed for this parameter)Result of the first sample (min:sec)Results after 30 min (*n*=)Results after 60 min (*n*=)Result of 100 samples (min:sec)Required time for 2 STAT samples with all 4 assays (min)**CS- 5100PT with Thromborel S (100%) APTT with Pathromtin SL (80%) AT with INNOVANCE AT (20%) D-Dimer with INNOVANCE D-Dimer (10%)08:28PT: 54 APTT: 44 AT: 12 D-Dimer: 6PT: 123 APTT: 99 AT: 25 D-Dimer: 1348:5109:01ACL TOPPT with RecombiPlasTin 2G (100%) APTT with SynthASil (80%) AT with Liquid Antithombin (20%) D-Dimer with D-Dimer HS 500 (10%)06:10PT: 40 APTT: 32 AT: 8 D-Dimer: 4PT: 87 APTT: 69 AT: 17 D-Dimer: 967:2419:58

The barcode reader showed very good functionality and was able to read e.g. distorted and crumpled barcodes. The problems in reading the barcode occurred when the barcode was very wet or when it was overwritten with a pencil.

4. Discussion {#s0065}
=============

This study compared the high-volume blood coagulation analyzer Sysmex CS-5100 System to the mid-volume blood coagulation analyzer Sysmex CS-2000*i* System for analytical performance. Additionally, these data were compared to the high-volume blood coagulation analyzer ACL TOP for operational performance.

The analytical performance for several assays on the CS-5100 was compared to that of the CS-2000*i* using the same Siemens reagents on both systems. The agreement between the two CS-systems was excellent. We show here for the first time a comparison of the CS-5100 and the CS-2000*i* or the ACL TOP, which included evaluation of the analytical and technical performance. The inter-assay CVs obtained were excellent at all concentrations measured. The results are similar to those obtained in other studies with fully automated coagulation analyzers ACL TOP [@bib5], [@bib6], Sysmex CA 6000 System [@bib7] and Sysmex CA-7000 System [@bib8].

As stated by the manufacturer, the CS-5100 has a higher throughput than the CS-2000*i*. Compared to the ACL TOP the CS-5100 showed considerably higher throughput while maintaining similar accuracy and imprecision.

For emergency (STAT) samples, a specific sampling position can be used which guarantees preferential treatment of the sample and fast results during routine operations.

During the study, the CS-5100 stopped once while it was measuring a high concentration made up of FVIII, von Willebrand factor antigen and INNOVANCE VWF Ac in a single blood sample taken from one patient. The cause of the stop was the fact that the CS-5100 had taken an insufficient volume of plasma aliquot from the total plasma sample. The device was thus unable to carry out a second measurement. Remarkably, this was the only system failure during the entire study period of 4 months. Since then, the error has been corrected by updating the software. Furthermore, no technical support was needed on site during the evaluation, showing that the system is robust.

The analyzer enables real-time monitoring of each sample status on-board, the status of the on-board time of each reagent and gives an overview of the number of tests that can be performed with this reagent volume. The software was extremely simple and intuitive to use.

Performance under stress conditions (running the system under simulated/provoked stress conditions) and usability during high throughput analysis were very good (data not shown).

Using the HIL check, the analyzer provides the routine technician with a fast and objective preanalytical sample check. However, some limitations were evident in an extremely lipemic sample.

Overall, the CS-5100 is excellent in terms of user needs and requirements under routine operating conditions.

The Sysmex CS-2000*i* System is not available for sale in the USA. Product availability varies by country.

Actin, Berichrom, Ci-Trol, Dade, INNOVANCE, Innovin, Pathromtin, ProC and Thromborel are trademarks of Siemens Healthcare Diagnostics Inc. or its affiliates.

Sysmex is a trademark of Sysmex Corporation.
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[^2]: PT: prothrombin time; APTT: activated partial thromboplastin time; Fib: fibrinogen, FII: factor II; FV: factor V; FVII factor VII; FVIII: factor VIII; FIX: factor IX; FX: factor X, FXI: factor XI; FXII: factor FXII; FXIII: factor XIII; PC: protein C; VWF Ag: von Willebrand factor antigen; VWF Ac: von Willebrand factor activity; APC-resistance: activated protein C-resistance.

[^3]: Abbreviations as in Table 1. N=Control Plasma N; P=Control Plasma P; C2=Dade Citrol 2, D1=D-Dimer control 1; D2=D-Dimer control 2. SD = standard deviation, CV=coefficient of variation.

[^4]: Abbreviations as in [Table 1](#t0005){ref-type="table"}. N= Control Plasma N; P = Control Plasma P. SD = standard deviation, CV = coefficient of variation.

[^5]: Abbreviations as in [Table 1](#t0005){ref-type="table"}

[^6]: Abbreviations as in [Table 1](#t0005){ref-type="table"}
